																				CI	10	MS	F	OF	₹M	
SUSPECT ADVERSE REACTION REPORT																										
												Ī							T	$\top$		$\top$	$\Box$			
	— )N I	NFOR	RM/	ATIC	NC																					
I. REACTION INFORMATION  1. PATIENT INITIALS 1a. COUNTRY 2. DATE OF BIRTH 2a. AGE 3. SEX 3a. WEIGHT 4-6 REACTION ONSET (first, last)												-	8-1			CK AL		E TO								
PRIVACY GUATEMALA Pay PRIVACY Year 82 Years Female 63.00 Pay kg											Mont	h		ear )22	,	Δ	ADV	ERSE	RE	ACTIO	NC					
economic factors	misu IND/	MLO 10-F34 by own decision and use by dose change] A 2.5 / AMLO 10-F34 even though her								INVOLVED OR PROLONGED INPATIENT HOSPITALISATION INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY  LIFE THREATENING  CONGENITAL ANOMALY  OTHER																
							(Conti						orma	ation	) Pa	ige)										
14. SUSPECT DRUG(S)	(include generic name)		II. SU	SPEC	<u>CT DR</u>	≀UG	3(S) IN	NFC	DRIV	1A I	ION						20. DID REACTION ABATE AFTER STOPPING									
,	IL ARG 10 / INDA 2.5	5 / AMLC	) 10-F34	(PERII	NDOPR		(Conti	inue	d on A	Addit	ional				•	ıge)	ABATE AFTER STOPPING DRUG?									
15. DAILY DOSE(S) #1 ) 0.5 DF, qd							) Oral u		ADMINI	ISTK#	I ION						YES NO NA									
17. INDICATION(S) FOR #1 ) Hypertension																	21. DID REACTION REAPPEAR AFTER REINTRODUCTION?									
, ,								. THERAPY DURATION  I ) Unknown									YES		NO	$\boxtimes$	NA	ı				
			. CON					S) A	ND	HIS	STO	R`	Y													
22. CONCOMITANT DRI	UG(S) AND DATES OF ADM	MINISTRAT	ION (exclud	le those us	sed to trea	at reac	tion)																			
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Type of History / Notes Description 1990 to Ongoing Historical Condition Hypertension (Hypertension) 2021 to Ongoing Historical Condition Osteoporosis (Osteoporosis)																										
			IV. M	IANUI	FACT	UR	ER IN	FO	RM	ATI	ON															
24a. NAME AND ADDRESS OF MANUFACTURER SERVIER CENTRO AMERICA Y CARIBE PANAMA							26. REMARKS Patient ID: 1811323620103 Study ID: IC4-06593-001-GTM*																			
24b. MFR CONTROL NO.  \$25012272  24c. DATE RECEIVED BY MANUFACTURER  20-AUG-2025  DATE OF THIS REPORT  26-AUG-2025  24d. REPORT SOURCE STUDY LITERATURE OTHER: OTHER:  25a. REPORT TYPE ALINITIAL FOLLOWUP:														Э.												

26-Aug-2025 16:57 Case Version: 1.0.56

## **ADDITIONAL INFORMATION**

## 7+13. DESCRIBE REACTION(S) continued

/ AMLO 10-F34 by own decision and economic factors, her doctor prescribed 1 tablet daily [Drug use for unapproved dosing regimen]

Case Description: This Solicited case was received from a Consumer in GUATEMALA concerned a patient participating in patient support program (PSP) protocol number IC4-06593 -001-GTM (Improve adherence to treatments).

The patient was an 82-years old female (patient ID: 1811323620103) with the medical history of hypertension since 1990 treated with PERINDOPRIL ARG 10 / INDA 2.5 / AMLO 10-F34 (half tablet daily, orally) from an unknown date in 2022 to an unknown date in FEB-2025 and osteoporosis since 2021.

No other concomitant treatments were reported, if any.

In 2022, she experienced Misuse because she took half tablet daily of PERINDOPRIL ARG 10 / INDA 2.5 / AMLO 10-F34 by own decision and economic factors, her doctor prescribed 1 tablet daily. If her blood pressure rose, she took PERINDOPRIL ARG 10 / INDA 2.5 / AMLO 10-F34 even though her doctor stopped her from taking it.

On an unknown date in FEB-2025, she experienced very low blood pressure and blocked kidney, her doctor suspended PERINDOPRIL ARG 10 / INDA 2.5 / AMLO 10-F34. She related the event Very low blood pressure to the kidney problems she had. She did not know the intensity.

O an unknown date in JUN-2025, she experienced urinary tract infection. It was not obtained to what she related it. The intensity was not obtained.

Treatment of the reaction (urinary tract infection): Since unknown date she took an antibiotic (she did not know the name).

Action taken regarding PERINDOPRIL ARG 10 / INDA 2.5 / AMLO 10-F34: Temporarily interrupted. In FEB-2025 doctor suspended PERINDOPRIL ARG 10 / INDA 2.5 / AMLO 10-F34.

Outcome: Recovered for Patient took half tablet daily of PERINDOPRIL ARG 10 / INDA 2.5 / AMLO 10-F34 by own decision and economic factors, her doctor prescribed 1 tablet daily, patient took PERINDOPRIL ARG 10 / INDA 2.5 / AMLO 10-F34even though her doctor stopped her from taking it, very low blood pressure and not recovered for blocked kidney, urinary tract infection.

The seriousness assessment as per reporter was non-serious.

Causality assessment was related for misuse- considered as not applicable for patient took half tablet daily of PERINDOPRIL ARG 10 / INDA 2.5 / AMLO 10-F34 by own decision and economic factors, her doctor prescribed 1 tablet daily and She took PERINDOPRIL ARG 10 / INDA 2.5 / AMLO 10-F34 even though her doctor stopped her from taking it.

Causality assessment was not related for Very low blood pressure, Blocked kidney and Urinary tract infection.

Consent to contact the doctor was not obtained.

Case Comment: Hydronephrosis and Urinary tract infection are unlisted while Hypotension is listed as per RSI of TRIPLIXAM (PERINDOPRIL ARGININE 10 mg, INDAPAMIDE 2.5 mg, AMLODIPINE 10 mg). Considering the known side effect and positive dechallenge for Hypotension the causal role is possible. While considering the missing information (detailed history, unspecified kidney problem, investigations, treatment of osteoporosis) and negative dechallenge the causal role is not related for Hydronephrosis and Urinary tract infection.

1	3.	Lab	Data

	#	Date	Test / Assess	ment / Notes	Results	Normal High / Low					
	1	FEB-2025	Blood pres	ssure measurement							
			low								
14-19. SUSPECT DRUG(S) continued											
14. SUSPECT DRUG(S) (include generic name)				15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION					
#1 ) PERINDOPRIL ARG 10 / INDA 2.5 /				0.5 DF, qd; Oral use	Hypertension (Hypertension)	2022 / FEB-2025;					
AMLO	10-F3	34 (PERINDOPRIL AF	RGININE 10		Unknown						

26-Aug-2025 16:57 Case Version: 1.0.56

Mfr. Control Number: S25012272

## **ADDITIONAL INFORMATION**

## 14-19. SUSPECT DRUG(S) continued

15. DAILY DOSE(S);
14. SUSPECT DRUG(S) (include generic name)
15. DAILY DOSE(S);
16. ROUTE(S) OF ADMIN
17. INDICATION(S) FOR USE
18. THERAPY DATES (from/to);
19. THERAPY DURATION

mg, INDAPAMIDE 2.5 mg, AMLODIPINE 10

mg) Tablet, 10/2.5/10 mg; Regimen #1

26-Aug-2025 16:57 Case Version: 1.0.56